|Videos|January 19, 2018

Understanding How Infectious Diseases Can Impact Cognitive Functionality

Robert Bransfield, MD, DLFAPA, explains how open minds are needed to understand how infections can impact cognitive function and conduct.

Robert Bransfield, MD, DLFAPA, private practice, Psychiatry, in Red Bank, New Jersey, explains how open minds are needed to understand how infections can impact cognitive function and conduct.

Interview Transcript (modified slightly for readability):

“We need open minds to look at this subject because it spans many different disciplines in science, and few people have expertise in all of those areas, so we need to use a multisystem approach. We can’t be narrow and rigid in looking at these problems, and I think that we could really achieve a lot by having a more cooperative scientific effort to understand how infections impact not just cognitive function or emotional impairment, but also conduct, behavior, and productivity.

I see this as a new era in psychiatry; we’ve evolved from psychiatry being demon possession to then being kind to the person and then that would help, and then Freud’s concept of insight, and then looking at the neurochemistry, but then something makes the neurochemistry go wrong. I think if we can understand that then we can help to prevent a lot of chronic things that trouble our society.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.